Format

Send to

Choose Destination
Med Mal Infect. 2018 Feb;48(1):23-29. doi: 10.1016/j.medmal.2017.10.010. Epub 2018 Jan 12.

Economic burden and cost-effective management of Clostridium difficile infections.

Author information

1
First department of internal medicine, university hospital of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
2
First department of internal medicine, university hospital of Cologne, Kerpener Straße 62, 50937, Cologne, Germany; German centre for infection research (DZIF), partner site Bonn-Cologne, Germany. Electronic address: maria.vehreschild@uk-koeln.de.

Abstract

Clostridium difficile infection (CDI) is the most important cause of healthcare-associated infectious diarrhea in industrialized countries. We performed a literature review of the overall economic burden of initial and recurrent CDI as well as of the cost-effectiveness of the various treatment strategies applied in these settings. Even though analysis of health economic data is complicated by the limited comparability of results, our review identified several internationally consistent results. Authors from different countries have shown that recurrent CDI disproportionally contributes to the overall economic burden of CDI and therefore offers considerable saving potential. Subsequent cost-effectiveness analyses almost exclusively identified fidaxomicin as the preferred treatment option for initial CDI and fecal microbiota transplant (FMT) for recurrent CDI. Among the various FMT protocols, optimum results were obtained using early colonoscopy-based FMT.

KEYWORDS:

Clostridium difficile infection; Cost-effectiveness; Coût-bénéfice; Infection à Clostridium difficile; Traitement; Treatment

PMID:
29336929
DOI:
10.1016/j.medmal.2017.10.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center